Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shree Pacetronix's ROE % for the quarter that ended in Mar. 2026 was 24.55%. Shree Pacetronix's PB Ratio for the quarter that ended in Mar. 2026 was 1.90.
Shree Pacetronix's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 12.92%.
Shree Pacetronix ROE % Adjusted to Book Value Related Terms
Shree Pacetronix ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Shree Pacetronix's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shree Pacetronix ROE % Adjusted to Book Value Chart
BOM:527005 vs ISRG, BDX, MDLN: ROE % Adjusted to Book Value Comparison
For the Medical Instruments & Supplies subindustry, Shree Pacetronix's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Pacetronix ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shree Pacetronix's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Shree Pacetronix's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 12.92% mean?
Shree Pacetronix (BOM:527005) has a ROE % Adjusted to Book Value of 12.92% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Shree Pacetronix and its competitors.
Is Shree Pacetronix's ROE % Adjusted to Book Value too high?
Shree Pacetronix's current ROE % Adjusted to Book Value is 12.92%. Overall, Shree Pacetronix has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shree Pacetronix's ROE % Adjusted to Book Value compare to ISRG and BDX?
Shree Pacetronix's ROE % Adjusted to Book Value of 12.92% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Shree Pacetronix and its competitors. Shree Pacetronix's current ROE % Adjusted to Book Value is 12.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Pacetronix stock overvalued right now?
Based on GuruFocus' analysis, Shree Pacetronix (BOM:527005) is currently considered Fairly Valued. The stock's GF Value™ is ₹163.30, compared to a current price of ₹151.35 — trading 7.3% below its estimated fair value. The current ROE % Adjusted to Book Value is 12.92%. Shree Pacetronix's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Shree Pacetronix (BOM:527005), the current ROE % Adjusted to Book Value is 12.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Pacetronix (BOM:527005) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Pacetronix stock appears to be undervalued.
The current stock price of ₹151.35 is trading 7.3% below its estimated GF Value™ of ₹163.30.
GuruFocus considers Shree Pacetronix to be Fairly Valued.
Key valuation signals for BOM:527005:
ROE % Adjusted to Book Value: 12.92%
GF Value™: ₹163.30 vs. price of ₹151.35 (7.3% below fair value)
No single metric tells the full story. See the BOM:527005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Pacetronix Ltd is engaged in the manufacturing of medical and surgical equipment and orthopedic appliances. It is in the business of manufacturing and selling Implantable Cardiac Pacemakers. Pacemakers are anti-bradycardia implantable devices intended for permanent ventricular or atrial pacing applications. The Company is engaged in only one segment i.e. Life Saving Devices. It sells its life-saving devices in India and internationally, of which the majority of revenue is generated from the sales made in India.
80GF Score
Get the complete analysis for BOM:527005
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:527005 has been successfully added to your 
